Asperitol (PB0182): Preliminary Results of Clinical Trial

1. Asperitol (PB0182): Preliminary Results of Clinical Trial Kyle Evans Landon Pharmaceuticals Testing, Inc. LPT Landon Pharmaceuticals Testing

2. Contents • Clinical Trial • Client Company and Test Dates • Medical Protocol • Participant Demographics • Medical Testing • Results • Summary and Recommendations Landon Pharmaceuticals Testing

3. Clinical Trial • FDA Application Number 9284773-08 • Phase III Trial • Target disease: rheumatoid arthritis • Drug name: Asperitol • Drug code number PB0182 Landon Pharmaceuticals Testing

4. Client Company and Test Dates • Contact information • Barbara Shao, Ph.D. • Parmerleau Biotechnologies • 105 Patriot Way • Newton, MA 02459 • Phone 402-555-4366 • Trial start date: February 12, 2008 • Trial completion date: September 15, 2010 Landon Pharmaceuticals Testing

5. Medical Protocol • Standard double-blind protocol • Sites of clinical trials • New York City • Tampa, Florida • Lincoln, Nebraska • Sacramento, California • Pre-tested participants at clinics • Administered dosage: 20-mg pill • Bi-monthly medical tests of participants Landon Pharmaceuticals Testing

6. Participant Demographics Landon Pharmaceuticals Testing

7. Medical Testing • Joint fluid analysis • Blood tests • Radiographs (x-rays) • Patient-reported pain levels (10-point scale) Landon Pharmaceuticals Testing

8. Results Landon Pharmaceuticals Testing

9. Summary and Recommendation • Dramatic decrease of symptoms in females suggests that Asperitol could be a commercial success in treating rheumatoid arthritis among women • Moderate decrease of symptoms in males suggest that for some men, Asperitol could be effective • Parmerleau should apply to FDA for approval to do Phase IV clinical trial Landon Pharmaceuticals Testing